These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 1471873)

  • 21. Redox imbalance.
    Berg D; Youdim MB; Riederer P
    Cell Tissue Res; 2004 Oct; 318(1):201-13. PubMed ID: 15365815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
    Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
    Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease.
    Soto-Otero R; Sanmartín-Suárez C; Sánchez-Iglesias S; Hermida-Ameijeiras A; Sánchez-Sellero I; Méndez-Alvarez E
    J Biochem Mol Toxicol; 2006; 20(5):209-20. PubMed ID: 17009235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxy-radical toxicity in catecholamine neurons.
    Cohen G
    Neurotoxicology; 1984; 5(1):77-82. PubMed ID: 6326007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative stress indices in Parkinson's disease : biochemical determination.
    Youdim MB; Drigues N; Mandel S
    Methods Mol Med; 2001; 62():137-53. PubMed ID: 21318773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
    Ebadi M; Sharma SK
    Antioxid Redox Signal; 2003 Jun; 5(3):319-35. PubMed ID: 12880486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress and the pathogenesis of Parkinson's disease.
    Jenner P; Olanow CW
    Neurology; 1996 Dec; 47(6 Suppl 3):S161-70. PubMed ID: 8959985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular role of catalase on oxidative stress-induced Ca(2+) signaling and TRP cation channel activation in nervous system.
    Nazıroğlu M
    J Recept Signal Transduct Res; 2012 Jun; 32(3):134-41. PubMed ID: 22475023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.
    Chiueh CC; Andoh T; Lai AR; Lai E; Krishna G
    Neurotox Res; 2000; 2(2-3):293-310. PubMed ID: 16787846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease--redox mechanisms.
    Adams JD; Chang ML; Klaidman L
    Curr Med Chem; 2001 Jun; 8(7):809-14. PubMed ID: 11375751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
    Youdim MB; Lavie L
    Life Sci; 1994; 55(25-26):2077-82. PubMed ID: 7527888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutathione--a review on its role and significance in Parkinson's disease.
    Martin HL; Teismann P
    FASEB J; 2009 Oct; 23(10):3263-72. PubMed ID: 19542204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.